Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pyrotinib|DRUG: SHR6390
Sponsor: Henan Cancer Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.